US Moderna today announced positive interim data in the Covid-19 vaccine study on children aged 6 to 12.
Covid, vaccine or disease protection lasts longer?
by Daniele Banfi
The analysis, the company said, showed a robust antibody response after two doses. Moderna plans to submit this data to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulators in the short term.
Covid Pfizer vaccine: more than 90 percent efficacy in children
Moderna did not release the complete data, and the results were not published in a peer-reviewed journal. The announcement was made in the run-up to the Food and Drug Administration’s analysis of data on a similar trial of Pfizer vaccine for the same age group.
Clinical studies of more than 4,700 children in this age group have shown a “robust” immune response in terms of antibody levels and a “favorable safety profile,” Moderna said in a statement.